Abstract
We conducted an observational single-center cohort study on patients with recurrent high-grade serous ovarian carcinoma that underwent secondary surgical cytoreduction with extent of partial ileectomy and/or colectomy, followed by adjuvant chemotherapy (Paclitaxel-Carboplatin). All patients performed previously primary debulking surgery without residual disease, followed by three cycles of adjuvant chemotherapy. The aim of this study was to compare survival in patients with ostomy or end-to-end anastomosis that underwent secondary cytoreduction. Furthermore, we investigated the morbidity, the rate, timing and complications of the ostomy or end-to-end anastomosis after secondary cyto-reduction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
All data is provided in the results section of this paper.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Katić K, Matković V, Lešin et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab—our experience. Libri Oncol 47(2–3):64–70
Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59–78
Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85
Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498
Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol 142(2):217–224
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259
Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74–78
Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60
Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519–1526
Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493–497
Coleman RL, Spirtos NM, Enserro D et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381:1929–1939
Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35:5501 (abstract)
Armstrong DK et al (2019) National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer (version 2.2018). J Natl Compr Canc Netw 17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039
Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543
National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017
Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36–41
Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955–3960
Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36
da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971–978
Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710
Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295
Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667–672
Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220–223
Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614
Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199–1206
Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185–1192
Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685–689
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Investigation LM; Conceptualization LM; Methodology MĆ; Supervision GV; Writing-Original Draft Preparation GS; Validation MM; Data Curation MM; Writing-Review and Editing GV.
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Matak, L., Mikuš, M., Ćorić, M. et al. Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study. Arch Gynecol Obstet 308, 231–237 (2023). https://doi.org/10.1007/s00404-023-06918-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-023-06918-9